scholarly journals Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy

2021 ◽  
Vol 7 (5) ◽  
pp. eabc7609
Author(s):  
Jia-Nan Cheng ◽  
Wen Luo ◽  
Chengdu Sun ◽  
Zheng Jin ◽  
Xianghua Zeng ◽  
...  

The efficacy of cancer immunotherapy is dictated by CD8+ T cell infiltration and the nature of the tumor microenvironment (TME). By inflaming the TME to favor CD8+ T cell immunity, radiation is now widely considered as a neoadjuvant for immunomodulation. Here, we observed that local irradiation enhances the infiltration of intratumoral eosinophils, and depletion of eosinophil dampens CD8+ T cell infiltration and diminishes the anti-tumor effectiveness of radiation. Retrospectively, we identified a strong correlation between eosinophilia and survival benefit in radiation-treated cancer patients. Experimentally, we further show that radiation enhances the intratumoral infiltration of adoptive transferred T cells therapy, bolstering eosinophils by intravenous interleukin-5 administration promotes the efficacy of radiation-induced abscopal effect. Together, these results suggest that eosinophil mobilization can be considered as a mechanistically relevant biomarker for predicting the effectiveness of pre-immunotherapy radiation, as well as a new strategy to enhance T cell-mediated immunotherapy against cancers.

Blood ◽  
2014 ◽  
Vol 124 (6) ◽  
pp. 963-972 ◽  
Author(s):  
Angela Mensen ◽  
Korinna Jöhrens ◽  
Ioannis Anagnostopoulos ◽  
Sonya Demski ◽  
Maike Oey ◽  
...  

Key Points Donor T-cell infiltration of the bone marrow is associated with impaired B-cell immunity after allogeneic HSCT. Quantification of κ-deleting recombination excision circles as a biomarker for bone marrow B-cell output in different clinical episodes.


Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 138
Author(s):  
Srikrishnan Rameshbabu ◽  
Brian W. Labadie ◽  
Anna Argulian ◽  
Akash Patnaik

The majority of current cancer immunotherapy strategies target and potentiate antitumor adaptive immune responses. Unfortunately, the efficacy of these treatments has been limited to a fraction of patients within a subset of tumor types, with an aggregate response rate of approximately 20% to date across all malignancies. The success of therapeutic inhibition of programmed death protein 1 (PD-1), protein death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with immune checkpoint inhibitors (ICI) has been limited to “hot” tumors characterized by preexisting T cell infiltration, whereas “cold” tumors, which lack T cell infiltration, have not achieved durable benefit. There are several mechanisms by which “cold” tumors fail to generate spontaneous immune infiltration, which converge upon the generation of an immunosuppressive tumor microenvironment (TME). The role of the innate immune system in tumor immunosurveillance and generation of antitumor immune responses has been long recognized. In recent years, novel strategies to target innate immunity in cancer therapy have emerged, including therapeutic stimulation of pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs); the DNA sensing cGAS/STING pathway; nucleotide-binding oligomerization domain-like receptors (NLRs), such as NLRP3; and the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs). In addition, therapeutic modulation of key innate immune cell types, such as macrophages and natural killer cells, has been investigated. Herein, we review therapeutic approaches to activate innate immunity within the TME to enhance antitumor immune responses, with the goal of disease eradication in “cold” tumors. In addition, we discuss rational immune-oncology combination strategies that activate both innate and adaptive immunity, with the potential to enhance the efficacy of current immunotherapeutic approaches.


Sign in / Sign up

Export Citation Format

Share Document